David Baltimore: The scientist who transformed biology and ushered in the biotech era

David Baltimore (1938-2025)

In September, David Baltimore — the scientist who discovered reverse transcriptase, a breakthrough often described as one of the most dramatic turning points in 20th-century biology — passed away. He was 87.

Baltimore was a pioneer whose work has led to a paradigm shift in the life sciences.

In 1953, Watson and Crick proposed the double-helix structure of DNA. Crick later articulated the flow of genetic information from DNA to RNA to protein, naming it the “central dogma” of molecular biology. Popularized through Watson’s textbooks, the concept became a foundational tenet of the life sciences for decades.

But in 1970, Howard Temin and David Baltimore discovered reverse transcriptase, demonstrating that RNA can be transcribed into DNA — a revelation that overturned the simplified, one-directional version of the dogma.

Kim Sun-young

Industrially, the enzyme proved transformative: By enabling the synthesis of cDNA from RNA templates, it became a key partner to recombinant DNA technology. It helped pave the way for the large-scale production of human therapeutic proteins in the 1980s. This marked the dawn of the modern biopharmaceutical industry.

Baltimore received the Nobel Prize in Physiology or Medicine at 37 — one of the youngest laureates in the prize’s history. Unlike many scientists whose research wanes after such recognition, his scientific output only expanded. His reach across experimental science, theory, administration, policy, and industry made him a true “Renaissance” scientist.

He credited his intellectual grounding to his mother, Gertrude Lipschitz, an experimental psychologist, noting in numerous interviews that she instilled in him critical thinking and independence from an early age — traits that would profoundly shape his scientific character.

In the 1960s, viruses served as powerful models for dissecting biological mechanisms. Through his research on poliovirus, Baltimore elucidated the replication strategies of RNA viruses, how polymerases are synthesized in the cytoplasm after infection, and how a single long polypeptide is cleaved into multiple functional proteins. His Nobel lecture succinctly captures this trajectory from poliovirus to retroviruses.

After earning his doctorate from Rockefeller University in 1964 at the age of 28, he joined the Salk Institute for Biological Studies and, three years later, moved to the Massachusetts Institute of Technology (MIT) as an assistant professor. Renato Dulbecco — who would later share the Nobel Prize with him — had recruited him to Salk, while Salvador Luria, the 1969 laureate and Watson’s doctoral adviser, encouraged him to make the move to MIT.

In 1982, with support from MIT, Baltimore founded the Whitehead Institute and became its first director. He boldly recruited young researchers and supported them intensively. Many leaders of the contemporary life sciences — including Eric Lander, Peter Kim, David Page and Ruth Lehmann — grew under his leadership.

During this period, his lab identified NF-κB and the RAG1 and RAG2 genes — molecules now recognized as central to adaptive immunity, with NF-κB in particular playing a key role in inflammation and cancer. At the time, I remember thinking he might well be headed for a second Nobel Prize.

His career, however, was not without turbulence. In the late 1980s, allegations of data manipulation in a paper by Thereza Imanishi-Kari escalated into a political scandal. Although Baltimore was not the senior author, his prominence made him an easy target. Congressman John Dingell, known for his combative style, pursued him relentlessly through repeated congressional hearings, transforming a scientific dispute into a national political spectacle.

Amid the fallout, Baltimore resigned as president of Rockefeller University just 18 months after taking office in 1990. A decade later, in 1996, Imanishi-Kari was formally cleared of wrongdoing, and Baltimore’s name was eventually restored. The episode remains a stark reminder of how destructive it can be when scientific debate becomes entangled in political agendas.

Back at MIT, Baltimore entered another period of remarkable productivity. His work on NF-κB and RAG deepened, and he made important contributions to HIV research. His standing in the scientific community only grew stronger.

In 1997, Caltech — one of the world’s premier science and engineering institutions — appointed him president. Over the next decade, he strengthened the university’s life-science infrastructure, secured major philanthropic funding and recruited promising young faculty. Even after stepping down in 2006, he maintained his laboratory, launched the Engineering Immunity program, and continued research on microRNAs, immunity and inflammation.

Baltimore also stood at the center of the nascent biotechnology industry. When recombinant DNA technology first emerged in the 1970s, he helped lead the 1975 Asilomar Conference on Recombinant DNA that established biosafety guidelines - later adopted by the NIH — allowing biotechnology to advance with public trust. In the 1980s, his work with emerging biotech ventures earned him a place among the so-called “molecular millionaires.”

He also played a balanced and influential role in the debates surrounding the Human Genome Project (HGP), including the “small science vs. big science” clash. Initially skeptical due to technological limitations, he reversed course as sequencing methods advanced rapidly, arguing that the HGP ultimately empowers research scientists by generating new tools and opportunities. His balanced guidance proved invaluable as the project moved forward.

Having worked in the Korean scientific community for 33 years, I have often felt that our greatest weakness is leadership. In a field full of brilliant minds, earning trust is no easy task. True leadership requires deep scientific insight, meaningful achievements that few can dispute, the ability to find and support young researchers, to bridge conflicting views, and to secure resources. Baltimore embodied all of these qualities.

Today, Korean science and technology stand at a crossroads, especially in the biosciences. Artificial intelligence is widening global disparities, and the life sciences now demand large-scale infrastructure and interdisciplinary collaboration. Yet we remain caught in debates over basic versus applied research, and in turf wars among departments built on outdated academic boundaries. Meanwhile, government priorities that shift every five years hinder the building of stable, long-term strategies.

In this time of rapid change, scientific leadership is more essential than ever. One can only hope that Korea, too, will someday produce a leader of Baltimore’s caliber.

Kim Sun-young is a professor emeritus at Seoul National University. He had worked with David Baltimore from 1987 to 1990.